AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.
The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.
AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.
The data is the first released by the company from its trials into boosters of its vaccine.
This is encouraging news, as per Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group, new data from ongoing Astazeneca/Oxford vaccine trials has shown that three doses give good protection against Omicron. https://t.co/kiXbbooFxc
— Adar Poonawalla (@adarpoonawalla) January 13, 2022
The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.
"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19," Oxford Vaccine Group chief Andrew Pollard said in a statement.
A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.
However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU